Clinical trials located in

Heraklion

Heraklion city is located in Greece. Currently, 20 clinical trials are being conducted in this city.

Heraklion, the vibrant capital of Crete, Greece, is steeped in ancient history and modern charm. Founded in 824 AD, it boasts the renowned Palace of Knossos, a testament to the advanced Minoan civilization. The city’s Venetian fortress, Koules, guards the old harbor, symbolizing Heraklion’s rich past. Home to the Historical Museum of Crete, Heraklion also celebrates the life and works of Nikos Kazantzakis, its famous son. Amidst its historical treasures, Heraklion thrives as a bustling urban center, blending the old with the new.

  • CT-EU-00117746

    Study of Pembrolizumab/Quavonlimab Combination vs Other Treatments for Colorectal Cancer

    This here clinical trial is aimin’ to take a good look at a new combination treatment called co-formulated pembrolizumab/quavonlimab for folks with stage IV colorectal cancer that’s got that microsatellite instability-high or mismatch repair deficient business goin’ on. The main goal is to see how well this new combo treatment works at shrinkin’ them tumors, compared to some other treatments out there.

    Now, the real important part is that the doctors’ll be keepin’ a close eye on how many folks get what they call an objective response, meanin’ their tumors either disappear completely or shrink down by at least 30%. They’ll be trackin’ this over a span of up to around 50 months to get a good picture of how effective this new treatment is.

    Safety’s always a top priority too, so the doctors’ll be watchin’ out for any side effects or issues that might crop up with this new combo treatment. It’s all about findin’ the best way to fight that cancer while keepin’ folks as comfortable as possible.

  • A study comparing upadacitinib versus adalimumab in the treatment of rheumatoid arthritis

    This clinical trial is studying a new medication called upadacitinib for treating moderate to severe rheumatoid arthritis. Rheumatoid arthritis is a chronic condition that causes pain, stiffness, swelling, and loss of joint function. The study will compare upadacitinib, which is taken as an oral tablet once daily, to adalimumab (brand name Humira), which is an injection given under the skin every other week.

    The main goal is to see how effective upadacitinib is at reducing disease activity compared to adalimumab. The study will measure the percentage of participants who achieve a certain level of low disease activity based on a score called the DAS28-CRP, which looks at tender and swollen joints, overall disease activity, and inflammation levels.

    This is a double-blind study, meaning neither the participants nor the study doctors will know which treatment each participant is receiving. Participants will attend regular visits at a hospital or clinic for medical assessments, checking for side effects, and completing questionnaires. There may be a higher treatment burden compared to standard care. The study is designed to assess the safety and effectiveness of upadacitinib compared to adalimumab in treating moderate to severe rheumatoid arthritis.

    • Adalimumab
    • Upadacitinib
  • Study on Ravulizumab’s effect on Immunoglobulin A Nephropathy

    The study is looking into the effectiveness of a medication called ravulizumab for adults who have a kidney condition known as Immunoglobulin A Nephropathy (IgAN). This condition can lead to kidney damage over time, and the study aims to find out if ravulizumab can help reduce the amount of protein lost in urine—a common problem in IgAN—and slow down the decrease in kidney function.

    In this study, about 450 participants who are at a high risk of their disease getting worse will be chosen. These participants must have been on stable treatment for their IgAN for at least three months before the study starts. They will then receive either ravulizumab or a placebo, which is a treatment with no active drug, through an IV infusion based on their weight. The main goal is to see if those who receive ravulizumab have a significant improvement in their condition compared to those who receive the placebo.

    The study will have two main checkpoints. The first one, at Week 34, will check how much protein is in the urine, and the second one, at Week 106, will assess how well the kidneys are filtering waste from the blood. Additionally, a smaller group of participants with more advanced kidney issues will receive ravulizumab to further explore its effects.

    After the study ends at Week 106, participants will have the option to continue receiving ravulizumab in a follow-up period to see how long-term treatment affects their condition. This study is a chance for people with IgAN to potentially slow down their disease progression and improve their quality of life.

    • placebo
    • Ravulizumab
  • Testing the effectiveness of new drugs in the treatment of age-related macular degeneration

    The study is investigating a potential breakthrough in treating age-related vision loss, specifically neovascular age-related macular degeneration (nAMD). It introduces a novel therapy, OPT-302, and pairs it with Aflibercept, comparing this combination’s effectiveness against the standard treatment. Participants undergo a series of thorough eye examinations and treatments to monitor the progression of their vision health. The research aims to offer a clearer understanding of how these treatments can better manage and possibly improve vision for individuals dealing with nAMD, contributing valuable knowledge to the field of eye health care.

    • aflibercept
    • OPT-302
  • Testing tozorakimab’s effect on chronic lung disease symptoms

    This study is all about testing a new drug, Tozorakimab, for people who have COPD – a lung disease that makes it difficult to breathe—and have had a bad flare-up in the past year. The researchers will give some people the new drug and some people a placebo (a dummy treatment) and see which works best. The drug is delivered in a shot under the skin, and all the people in the study will also keep taking their usual COPD medicines. The main things the researchers will be looking at are whether the new drug can reduce the number of flare-ups, improve quality of life (measured using a questionnaire), reduce the need for rescue medication and if it changes the results of breathing tests.

    • Tozorakimab
  • Study of the effectiveness of tanimilast in the treatment of pulmonary diseases

    A 52-week clinical trial is being conducted to investigate the effectiveness and safety of the new drug, known as Tanimilast (CHF6001), in people diagnosed with chronic bronchitis and chronic obstructive pulmonary disease (COPD). The primary aim of the study is to determine the effectiveness of CHF6001 administered as an addition to a standard COPD treatment regimen. Study participants will be randomly assigned to receive the study drug CHF6001 or a placebo, which will be taken concurrently with their existing COPD therapy. Key measurements in the study include monitoring the frequency and severity of COPD exacerbations, which are episodes of significantly worsening symptoms. Additionally, the study will assess changes in participants’ lung function and overall quality of life. Typically eligible for the study are adults who are 40 years of age or older, have a documented history of COPD and chronic bronchitis, and are current or former smokers. In particular, the study is of interest to people who have experienced at least one COPD exacerbation in the year preceding the study.

    • Tanimilast/CHF6001
    • Roflumilast
  • Improving psoriasis treatment for patients: a study on brodalumab

    This detailed study focuses on individuals with moderate-to-severe plaque psoriasis who weigh more than 120 kg. It aims to find out if adjusting the dose of the medication brodalumab can lead to better skin health. In this study, participants receive either an adjusted higher dose of brodalumab or the standard dose. Researchers closely monitor the skin’s response to the treatment, checking if the adjusted dose leads to better skin clearance, meaning fewer or no psoriasis symptoms.

    • Brodalumab
  • Study of new drug ARV-471 (PF-07850327) and fulvestrant in patients with advanced breast cancer

    The study looks at advanced breast cancer that has spread to other parts of the body (metastasizes). It is aimed at patients with ER+/HER2- breast cancer, which means that the cancer responds to estrogen (a hormone) and does not have excessive amounts of the HER2 protein. The study will compare two drugs: ARV-471 (PF-07850327, vepdegestrant) and fulvestrant.

    Fulvestrant is a drug already used to treat breast cancer, while ARV-471 is a new drug. The aim of this study is to determine whether ARV-471 is safe and effective compared to fulvestrant in patients with advanced breast cancer that cannot be cured by surgery or radiotherapy.

    The study is open to adults with breast cancer recurrence or metastases that cannot be fully cured by surgery or radiotherapy. Candidates should have a confirmed diagnosis of ER+/HER2- breast cancer and previous treatment with CDK4/6 inhibitors combined with hormonal therapy. Patients must not have active brain metastases or liver, kidney or bone marrow failure.

    Treatment continues until the cancer gets worse or the side effects become too severe. Clinic meetings take place approximately every 4 weeks.

    • Vepdegrestrant/ARV-471
    • Fulvestrant
  • Study of Tucatinib, Trastuzumab and Pertuzumab in the treatment of HER2+ metastatic breast cancer

    The study is aimed at patients with HER2-positive breast cancer whose disease has spread locally, i.e. close to where it started, and cannot be surgically removed, or has spread to other parts of the body. Treatment in this study includes a combination of drugs: tucatinib (also known as TUKYSA, ONT-380, ARRY-380), trastuzumab (Herceptin, Herceptin Hylecta), and pertuzumab (Perjeta). Some patients will receive a placebo instead of tucatinib.

    All patients will receive trastuzumab and pertuzumab, plus either tucatinib or placebo. Trastuzumab is administered intravenously (IV) or subcutaneously, and pertuzumab is administered intravenously. In some cases, trastuzumab and pertuzumab may be administered subcutaneously in combination.

    The aim of the study is to check whether tucatinib in combination with trastuzumab and pertuzumab works better than placebo. This will also check what side effects may occur while taking this drug combination. Side effects are any adverse effects a drug may have on the body in addition to treating the disease.

    The study includes patients who have already undergone 4-8 cycles of pre-treatment with trastuzumab, pertuzumab and taxane as first-line treatment for advanced breast cancer, and do not show disease progression after completion of this pre-therapy. Patients can have both positive and negative hormone receptor status.

    • Pertuzumab
    • Tucatinib
    • Trastuzumab
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    • Zanubrutinib
    • Obinutuzumab
    • Lenalidomide
    • Rituximab
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    • Dazostinag
    • Platinum
    • Pembrolizumab
    • 5-Fluorouracil
  • Assessing olpasiran treatment for heart disease and elevated cholesterol

    Tests named ‘OCEAN(a)’ are being conducted, focusing on a medication called ‘olpasiran’. Put simply, the potential of this medication in preventing serious heart episodes in individuals with Atherosclerotic Cardiovascular Disease and an elevated level of a fat protein, Lipoprotein(a), is under examination. The effect of a harmless, dummy pill (placebo) is compared to that of the actual medication, olpasiran, in individuals with these conditions. The primary goal is to determine whether olpasiran can reduce the risk of death due to heart disease, occurrence of heart attacks, or the necessity for sudden surgery to clear blocked heart vessels.

    • Olpasiran
  • Testing the effect and safety of tanimilast for COPD patients

    This study is a year-long experiment where the researchers will test the effectiveness and safety of two doses of a new drug called tanimilast. Tanimilast is added to the usual treatment for people with two lung conditions: COPD and Chronic Bronchitis. The drug will be tested and compared with a group that will take a placebo, a substance with no effect. The main aim is to see if tanimilast helps control the worsening of symptoms in COPD patients. These worsening instances are known as ‘exacerbations’ and can range in severity. Some might require extra medication.

    • Tanimilast/CHF6001
  • Testing efavaleukin alfa’s effect on moderately to severely active ulcerative colitis

    This trial is about a drug named efavaleukin alfa, which might be helpful for people suffering from ulcerative colitis. Participants will either receive one of three doses of this drug or placebo for 12 weeks. If the treatment works, participants can choose to continue it for up to 52 weeks. If initially received placebo didn’t work, treatment will be switched to efavaleukin alfa.

    • Efavaleukin alfa
  • A breast cancer study that compares Sacituzumab Govitecan with other therapies for patients with HR+/HER2- metastatic breast cancer who were receiving hormone therapy

    The clinical trial is aimed at patients with hormone-dependent (HR+) and HER2-negative (HER2-) metastatic breast cancer who have received hormonal therapy.

    The study will evaluate the effects of Sacituzumab Govitecan-hziy (SG) compared to physician-selected standard therapies such as Paclitaxel, Nab-paclitaxel or Capecitabine, in patients with metastatic or locally advanced breast cancer that is not operable. Sacituzumab Govitecan-hziy is an experimental drug that may extend patients’ lives and inhibit the growth or spread of tumors.

    The main objectives of the study are to evaluate progression-free survival (PFS) and overall survival (OS). Response to treatment, changes in quality of life related to physical functioning, and time to deterioration in various quality of life domains will also be assessed.

    The study includes patients who have shown disease progression after at least two previous lines of hormone therapy for advanced breast cancer. Patients must have an adequate tumor sample from the site of recurrence or metastasis and be candidates for first chemotherapy in advanced disease.

    • Sacituzumab Govitecan-hziy
    • nab-Paclitaxel
    • Capecitabine
    • Paclitaxel
  • Testing venglustat for heart condition in Fabry disease patients

    This study is about a medicine called venglustat, and how it affects the size of the left side of the heart for people with a disease called Fabry. The trial will have men and women with Fabry disease, who will either get venglustat or the current commonly used treatments. The aim is to investigate whether venglustat can induce changes in the size of the left side of the hearts. The trial will last for 18 months, with check-ups every 3 to 6 months. After the first 18 months, patients can choose to get venglustat for 34 more months. So, the whole study could last up to 4.4 years for some people.

    • Agalsidase beta/GZ419828
    • Venglusat/GZ402671
    • Agalsidase alfa
    • Migalastat
  • Exploring leramistat’s potential in treating lung fibrosis

    This study investigates the effectiveness of leramistat in adults with idiopathic pulmonary fibrosis (IPF). Participants, aged 40 or older, will receive either leramistat or a placebo for 12 weeks. The study will examine leramistat’s impact on lung function, especially how much air they can breathe out. The study is to understand if leramistat can be a new treatment for IPF.

    • Leramistat
  • Testing the safety and effectiveness of a new drug in the treatment of pulmonary fibrosis

    This study is testing a new drug called BMS-986278 for a lung disease called progressive pulmonary fibrosis. This condition causes the lungs to become increasingly scarred over time, making breathing difficult. Randomly assigned participants will receive either the real drug or a fake drug (placebo) that doesn’t work. No one will know who gets what, not even doctors. The goal is to see if this new drug helps slow the progression of the disease, prevent patients from having to be hospitalized and/or increase their chances of survival. These outcomes will be measured by tracking breathing tests, any sudden, serious worsening of the disease, any hospital stays related to lung disease, and any deaths from any cause.

    • BMS-986278- new potential medication for idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF)
  • Study of Early Breast Cancer Using Camizestrant or Hormone Therapy for Patients at Risk of Recurrence After At Least 2 Years of Standard Therapy

    The clinical trial focuses on patients with early-stage ER+/HER2- breast cancer, meaning the cancer is hormone-receptor-positive (ER+) and does not have an excess of the HER2 protein (HER2-). Participants must have an intermediate or high risk of disease recurrence and must have completed definitive locoregional therapy (such as surgery or radiotherapy) and at least 2 years but not more than 5 years of standard hormone therapy.

    The aim of the study is to assess the efficacy and safety of the drug Camizestrant (AZD9833) compared to standard hormone therapy, which may include aromatase inhibitors (e.g., letrozole, anastrozole, exemestane) or tamoxifen.

    Key measures will include the time to the recurrence of invasive breast cancer, invasive disease-free survival, distant relapse-free survival, overall survival, and the safety of the therapies used.

    Both women and men over 18 years old who meet specific criteria can participate in the study. Therapeutic effects and potential side effects will be monitored during the treatment. Patients will be observed for 10 years from the time of randomization into one of the study groups.

    • camizestrant
    • Anastrozole
    • Letrozole
    • Exemestane
    • tamoxifen
  • Study of Dato-DXd and durvalumab in persistent triple-negative breast cancer

    This trial is about testing a combination of new treatments for triple-negative breast cancer which hasn’t fully responded to the first line of treatment. The new treatment includes a drug called Dato-DXd and a known drug called Durvalumab, both administered individually, or as a combination. This is compared to an already established treatment recommended by the doctor. The researchers are mainly interested in delaying the return of the cancer, and if the new drug with or without Durvalumab does a better job at this than the doctor-recommended treatment. Along with this main goal, the trial will also monitor how these treatments affect patients’ routine activities, their well-being, their levels of fatigue, the amount of Dato-DXd and related components present in the body, and any side effects and potential risks associated with these treatments.

    • Dato-DXd
    • Pembrolizumab
    • Capecitabine
    • Durvalumab

See more clinical trials in other cities in Greece:

.